Skip to main content
Top
Published in: Cancer Imaging 1/2015

Open Access 01-12-2015 | Research article

The presurgical T staging of non-small cell lung cancer: efficacy comparison of 64-MDCT and 3.0 T MRI

Authors: Wei Tang, Ning Wu, Han OuYang, Yao Huang, Li Liu, Meng Li

Published in: Cancer Imaging | Issue 1/2015

Login to get access

Abstract

Background

Lung cancer has been the main concern of the cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is reported the most common subtype of lung cancer. Initial staging of NSCLC is highly associated with the choice of treatment and prognosis of the patients. This study aims to prospectively compare the diagnostic efficacies of 64-multidetector-row computed tomography (MDCT) and 3.0 T magnetic resonance imaging (MRI) in T staging of NSCLC. 

Methods

Institutional review board approval and informed consent were obtained. Forty-five patients diagnosed with NSCLC who underwent preoperative MRI and MDCT scans were enrolled in the study. The efficacies of determination of T staging on MRI and MDCT were compared by using the McNemar test.

Results

Of 45 patients diagnosed with NSCLC, the primary tumors were correctly staged in 38 (84.4 %) patients on MDCT, and in 37 (82.2 %) patients on MRI. There was no statistically significant difference between the two modalities in the overall T staging of NSCLC with the reference of pathological findings (p = 0.564). However, MDCT was indicated more accurate in determination of NSCLC staged T1 and T2 (100 % vs 75 %, 96.4 % vs 82.1 %), whereas MRI was presented slightly superior in identification of NSCLC staged T3 and T4 (80 % vs 50 %, 100 % vs 33.3 %).

Conclusion

Both MDCT and MRI provided acceptable overall accuracies in determination of T staging in NSCLC. Furthermore, MRI was presented slight superiority for the advanced-stage tumors (i.e., NSCLC staged T3 and T4), whereas MDCT was indicated mild acceptance for the limited-stage tumors (i.e., NSCLC staged T1 and T2).
Literature
2.
go back to reference American Cancer Society. Cancer facts and figures 2011. Atlanta (GA): American Cancer Society; 2011. American Cancer Society. Cancer facts and figures 2011. Atlanta (GA): American Cancer Society; 2011.
3.
go back to reference Milina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRef Milina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRef
4.
go back to reference Wynants J, Stroobants S, Dooms C, Vansteenkiste J. Staging of lung cancer. Radiol Clin North Am. 2007;45:609–25.CrossRefPubMed Wynants J, Stroobants S, Dooms C, Vansteenkiste J. Staging of lung cancer. Radiol Clin North Am. 2007;45:609–25.CrossRefPubMed
5.
go back to reference The American Thoracic Society, European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997;156:320–332. The American Thoracic Society, European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997;156:320–332.
6.
go back to reference Venuta F, Rendina E, Ciriaco P. Computed tomography for preoperative assessment of T3 and T4 bronchogenic carcinoma. Eur J Cardiothorac Surg. 1992;6:238–41.CrossRefPubMed Venuta F, Rendina E, Ciriaco P. Computed tomography for preoperative assessment of T3 and T4 bronchogenic carcinoma. Eur J Cardiothorac Surg. 1992;6:238–41.CrossRefPubMed
7.
go back to reference Imai K, Minamiya Y, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. Use of CT to evaluate pleuralinvasion in non–small cell lung cancer: measurement of the ratio of the interface between tumor andneighboring structures to maximum tumor diameter. Radiology 2013; 267 (2): 619-626. Imai K, Minamiya Y, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. Use of CT to evaluate pleuralinvasion in non–small cell lung cancer: measurement of the ratio of the interface between tumor andneighboring structures to maximum tumor diameter. Radiology 2013; 267 (2): 619-626.
8.
go back to reference Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. Am J Roentgenol. 1995;164(6):1349–59. Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. Am J Roentgenol. 1995;164(6):1349–59.
9.
go back to reference Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. 1994;190:841–6. Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. 1994;190:841–6.
10.
go back to reference Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0 T whole-body MRI. Radiology. 2008;248(2):632–42. Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0 T whole-body MRI. Radiology. 2008;248(2):632–42.
11.
go back to reference Lee VS, Hecht EM, Taouli B, Chen Q, Prince K, Oesingmann N. Body and cardiovascular MR imaging at 3.0 T. Radiology. 2007;244:692–706. Lee VS, Hecht EM, Taouli B, Chen Q, Prince K, Oesingmann N. Body and cardiovascular MR imaging at 3.0 T. Radiology. 2007;244:692–706.
12.
go back to reference Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178(3):705–13. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178(3):705–13.
13.
go back to reference White CS. MR evaluation of the pericardium and cardiac malignancies. Magn Reson Imaging Clin N Am. 1996;4(2):237–51.PubMed White CS. MR evaluation of the pericardium and cardiac malignancies. Magn Reson Imaging Clin N Am. 1996;4(2):237–51.PubMed
14.
go back to reference Ohno Y, Adachi S, Motoyama A, Kusumoto M, Hatabu H, Sugimura K, et al. Multiphase ECG-triggered 3D contrast-enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging. 2001;13(2):215–24. Ohno Y, Adachi S, Motoyama A, Kusumoto M, Hatabu H, Sugimura K, et al. Multiphase ECG-triggered 3D contrast-enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging. 2001;13(2):215–24.
15.
go back to reference Londy FJ, Lowe S, Stein PD, Weq JG, Eisner RL, Leeper KV, et al. Comparison of 1.5 and 3.0 T for contrast-enhanced pulmonary magnetic resonance angiography. Clin Appl Thromb Hemost. 2012;18:134–9. Londy FJ, Lowe S, Stein PD, Weq JG, Eisner RL, Leeper KV, et al. Comparison of 1.5 and 3.0 T for contrast-enhanced pulmonary magnetic resonance angiography. Clin Appl Thromb Hemost. 2012;18:134–9.
16.
go back to reference Facciolo F, Cardillo G, Lopergolo M, Pallone G, Sera F, Martelli M. Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection. J Thorac Cardiovasc Surg. 2001;123(4):649–56. Facciolo F, Cardillo G, Lopergolo M, Pallone G, Sera F, Martelli M. Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection. J Thorac Cardiovasc Surg. 2001;123(4):649–56.
17.
go back to reference Burkhart HM, Allen MS, Nichols 3rd FC, Deschamps C, Miller DL, Trastek VF, et al. Results of en bloc resection for bronchogenic carcinoma with chest wall invasion. J Thorac Cardiovasc Surg. 2002;123(4):670–5. Burkhart HM, Allen MS, Nichols 3rd FC, Deschamps C, Miller DL, Trastek VF, et al. Results of en bloc resection for bronchogenic carcinoma with chest wall invasion. J Thorac Cardiovasc Surg. 2002;123(4):670–5.
18.
go back to reference Padovani B, Mouroux J, Seksik L, Chanalet S, Sedat J, et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology. 1993;187(1):33–8.CrossRefPubMed Padovani B, Mouroux J, Seksik L, Chanalet S, Sedat J, et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology. 1993;187(1):33–8.CrossRefPubMed
19.
go back to reference Bonomo L, Ciccotosto C, Guidotti A, Storto ML. Lung cancer staging: the role of computed tomography and magnetic resonance imaging. Eur J Radiol. 1996;23(1):35–45.CrossRefPubMed Bonomo L, Ciccotosto C, Guidotti A, Storto ML. Lung cancer staging: the role of computed tomography and magnetic resonance imaging. Eur J Radiol. 1996;23(1):35–45.CrossRefPubMed
20.
go back to reference Higashino T, Ohno Y, Takenaka D, Watanabe H, Nogami M, Ohbayashi et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol. 2005;56(1):48–55. Higashino T, Ohno Y, Takenaka D, Watanabe H, Nogami M, Ohbayashi et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol. 2005;56(1):48–55.
Metadata
Title
The presurgical T staging of non-small cell lung cancer: efficacy comparison of 64-MDCT and 3.0 T MRI
Authors
Wei Tang
Ning Wu
Han OuYang
Yao Huang
Li Liu
Meng Li
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2015
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-015-0050-4

Other articles of this Issue 1/2015

Cancer Imaging 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine